CLDX — Celldex Therapeutics Inc

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$31.65
Market Cap$2.40B
Float72.5M
Shares Outstanding78.5M
Price/Sales (TTM)2,774.90
vs. Analyst Target+84.6% to analyst PT
Operating Margin (TTM)-562900.00%
Revenue (TTM)$865,000
Dividend RateNone
Analyst Target Price$58.43 (15 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $7.4M -$59.8M -$35.1M -$45.6M
2021 $4.7M -$70.5M -$48.7M -$66.1M
2022 $2.4M -$112M -$79.9M -$104M
2023 $6.9M -$141M -$111M -$139M
2024 $7.0M -$158M -$157M -$192M
2025 $1.5M -$259M $1.5M -$255M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $730,000 -$56.6M
Sep 2025 N/A -$67.0M
Dec 2025 $75,000 -$81.4M
Mar 2026 $15,000 -$78.7M

Ownership & Float

Insider Ownership0.3%
Institutional Ownership94.4%
Short Float10.5%
% of All Funds Holding2.52%
Number of Funds Holding207

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$32.14Near-term / short-term trend
Weekly40-Week SMA$27.64Medium-term trend
Weekly80-Week SMA$24.88Cyclical trend (business cycle)
Weekly200-Week SMA$31.25Secular trend (multi-year)
Monthly10-Month SMA$27.98Near-term monthly trend
Monthly20-Month SMA$25.24Medium-term monthly trend
Monthly40-Month SMA$30.28Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$21.90 support 1.32x 7 months ago
$33.90 resistance 1.15x 18 months ago
$41.00 resistance 1.80x 19 months ago
$47.00 resistance 1.64x 25 months ago

Historical Earnings Reactions (118 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.47% 0.00% 42.37% 10.41% -21.31%
1 Day -0.18% 0.00% 45.76% 17.45% -20.99%
1 Week -0.65% -1.68% 41.53% 44.98% -26.42%
2 Weeks -1.05% -0.27% 46.61% 38.24% -49.64%
1 Month -0.37% -2.08% 45.30% 89.84% -47.90%

Next earnings: July 26, 2026 (59 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan12.3%55.0%40
Feb-0.4%42.5%40
Mar0.6%47.5%40
Apr0.3%50.0%40
May-2.1%28.2%39
Jun14.5%50.0%40
Jul-1.2%42.5%40
Aug-2.8%37.5%40
Sep-1.8%32.5%40
Oct0.5%50.0%40
Nov5.8%57.5%40
Dec-0.8%45.0%40

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -0.19% 39.5% 1901
Tuesday 0.07% 42.0% 2070
Wednesday 0.21% 42.1% 2067
Thursday 0.15% 42.2% 2027
Friday 0.26% 42.5% 2018

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 94.4%

Insider Transactions — Smart Summary

Total insider ownership: 0.3%

Founder-led management: Anthony Marucci (Founder, President, CEO & Director), Tibor Keler (Founder, Chief Scientific Officer & Executive VP)

12-Month Insider Activity Summary

Total Filings3
Net Value-$140,305.667
Net Shares Change-4,937
% of Float-0.0%
C-Suite Filings2
Clusters Detected0

Key Insiders

NameTitleNet ValueFilingsActivity
Wright Richard M. -$490,263.68 1 1 sell
Jimenez Freddy A. SVP and GENERAL COUNSEL -$140,305.667 2 2 sell

Significant Filings

DateInsiderTitleNet ValuePrice After
2025-12-08 Jimenez Freddy A. SVP and GENERAL COUNSEL -$121,209.77 Transaction at $29.09, now +8.8%
2025-08-15 Jimenez Freddy A. SVP and GENERAL COUNSEL -$19,095.897 Transaction at $24.77, now +27.8%
2025-11-17 Wright Richard M. -$490,263.68 Transaction at $19.03, now +66.3%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Celldex Therapeutics Inc (CLDX) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for CLDX on Trend Edge →